[{"id":"E02","lang":"en","question":"What drugs are in PharmaEssentia’s pipeline besides BESREMi?","answer":[{"text":"PharmaEssentia’s published early-stage pipeline lists anti-PD-1 P1801 for solid tumors and PEG-GCSF P2203 for neutropenia.","fact_ids":["f1","f2"]},{"text":"The same pipeline also lists TCR-T for solid tumors and PEG-cytokines, including IL-2, for solid tumors and immunology.","fact_ids":["f3","f4"]},{"text":"Other listed programs include novel checkpoint antibodies for solid and hematologic tumors, a bispecific immunocytokine for solid tumors, and P1101 plus anti-PD-1 for HCC.","fact_ids":["f5","f6","f7"]}],"facts":[{"id":"f1","claim":"Anti-PD-1 candidate","value":"P1801; solid tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"anti PD-1 (P1801)"},{"id":"f2","claim":"PEG-GCSF candidate","value":"P2203; neutropenia","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"PEG-GCSF (P2203)"},{"id":"f3","claim":"Cell therapy candidate","value":"TCR-T; solid tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"TCR-T"},{"id":"f4","claim":"Cytokine candidates","value":"PEG-cytokines, including IL-2; solid tumors and immunology","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"PEG-cytokines (e.g., IL-2)"},{"id":"f5","claim":"Checkpoint antibodies","value":"Novel checkpoint antibodies; solid and hematologic tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"Novel checkpoint Abs"},{"id":"f6","claim":"Bispecific immunocytokine","value":"Solid tumors","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"Immunocytokine"},{"id":"f7","claim":"Combination program","value":"P1101 plus anti-PD-1; HCC","as_of":"2026-10-22","source":"https://us.pharmaessentia.com/innovation/technology/","quote":"P1101"}],"undisclosed":{"text":"The checked public pipeline does not provide an exact next readout or approval date for these early-stage programs.","source":"https://us.pharmaessentia.com/innovation/technology/","as_of":"2026-10-22","quote":"Robust Early-Stage Pipeline","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"answered","limitations":["Program identities and indications are verified; no stage is inferred from flattened graphical progress bars."]},{"id":"E05","lang":"en","question":"What upfront payment did AstraZeneca pay insitro?","answer":[{"text":"The disclosed upfront commitment is US$40 million: insitro’s October 15, 2026 announcement says it will receive that amount under its AstraZeneca collaboration.","fact_ids":["f1"]},{"text":"The announcement also lists up to approximately US$1.46 billion in potential discovery, development and commercial milestones, plus single-digit royalties.","fact_ids":["f2","f3"]}],"facts":[{"id":"f1","claim":"Upfront commitment","value":"USD 40,000,000","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"$40 million upfront"},{"id":"f2","claim":"Potential milestone ceiling","value":"Approximately USD 1,460,000,000","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"$1.46 billion"},{"id":"f3","claim":"Royalties","value":"Single-digit royalties on potential global commercial sales","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"single-digit royalties"}],"undisclosed":{"text":"The checked public announcement does not establish that the upfront payment has already been received or disclose exact royalty tiers.","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","as_of":"2026-10-22","quote":"will receive","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["Disclosed contractual amount; cash receipt is not verified."]},{"id":"E06","lang":"en","question":"Has TaiGen disclosed an FDA PDUFA date for its influenza drug TG-1000?","answer":[{"text":"No FDA PDUFA date for TG-1000 was found in the TaiGen product and milestone pages checked on October 22, 2026.","fact_ids":["f1","f2"]},{"text":"TaiGen’s milestone page records a China NDA submission in August 2024 and an FDA IND filing in October 2020.","fact_ids":["f1","f2"]}],"facts":[{"id":"f1","claim":"China regulatory filing","value":"NDA submitted in mainland China in August 2024","as_of":"2024-08","source":"https://www.taigenbiotech.com/en/about/milestone","quote":"A New Drug Application (NDA)","date_precision":"month"},{"id":"f2","claim":"US regulatory filing","value":"FDA IND filed in October 2020","as_of":"2020-10","source":"https://www.taigenbiotech.com/en/about/milestone","quote":"TaiGen filed IND application","date_precision":"month"}],"undisclosed":{"text":"The checked public company pages do not disclose a U.S. NDA acceptance or FDA review goal date for TG-1000.","source":"https://www.taigenbiotech.com/en/product","as_of":"2026-10-22","quote":"Pixavir (TG-1000)","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["Search-limited negative finding; not a claim that no date exists anywhere."],"absence_audit":{"checked_sources":["https://www.taigenbiotech.com/en/about/milestone","https://www.taigenbiotech.com/en/product"],"terms":["PDUFA","goal date","review date","US NDA"],"checked_at":"2026-10-22"}},{"id":"E10","lang":"en","question":"How are TaiMed, Theratechnologies, and Trogarzo connected?","answer":[{"text":"TaiMed identifies Theratechnologies as its exclusive U.S. commercialization partner for Trogarzo (ibalizumab-uiyk).","fact_ids":["f1"]},{"text":"TaiMed’s 2025 statement says their longstanding agreement for marketing and distributing Trogarzo in the United States and Canada remains in effect despite the announced Future Pak transaction.","fact_ids":["f2"]}],"facts":[{"id":"f1","claim":"Product and US partner","value":"Trogarzo (ibalizumab-uiyk); Theratechnologies is TaiMed’s exclusive U.S. commercialization partner","as_of":"2026-10-22","source":"https://www.taimedbiologics.com/article_d.php?id=2922&lang=en&tb=5","quote":"exclusive commercialization partner"},{"id":"f2","claim":"Distribution relationship","value":"TaiMed–Theratechnologies agreement covers marketing and distribution in the U.S. and Canada","as_of":"2026-10-22","source":"https://www.taimedbiologics.com/article_d.php?id=2922&lang=en&tb=5","quote":"in the U.S. and Canada remains in effect"}],"undisclosed":{"text":"The checked public partnership-continuity statement does not disclose the full contract, current transfer-price formula or product-level profit split.","source":"https://www.taimedbiologics.com/article_d.php?id=2922&lang=en&tb=5","as_of":"2026-10-22","quote":"TaiMed Biologics","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","document_note":"The cited statement is labeled 2025 without an exact publication day; as_of is the access date, not the announcement date.","limitations":["Current relationship is supported by a dated-year company statement; exact publication day and full contract are not disclosed."]},{"id":"E13","lang":"en","question":"What is GlycoNex’s GNX102 and which clinical stage has it reached?","answer":[{"text":"GNX102 is GlycoNex’s humanized monoclonal antibody targeting tumor-associated glycan structures; its registered study NCT04250597 was Phase 1.","fact_ids":["f1","f2"]},{"text":"The record last updated on May 6, 2024 lists the trial as TERMINATED and says the expansion phase was not performed following the sponsor’s business decision after the maximum tolerated dose was reached.","fact_ids":["f3","f4"]},{"text":"GlycoNex’s current pipeline separately lists GNX1021 as a clinical-stage ADC, so its Phase 1 status should not be assigned to GNX102.","fact_ids":["f5"]}],"facts":[{"id":"f1","claim":"Modality and target","value":"Humanized monoclonal antibody targeting novel tumor glycan structures","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"GNX102 is a humanized monoclonal antibod"},{"id":"f2","claim":"Registered phase","value":"NCT04250597; PHASE1","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"PHASE1"},{"id":"f3","claim":"Trial status","value":"TERMINATED; last posted update 2024-05-06","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"TERMINATED"},{"id":"f4","claim":"Reason stopped","value":"Maximum tolerated dose reached; expansion not performed per sponsor business decision","as_of":"2024-05-06","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","quote":"Maximum tolerated dose reached"},{"id":"f5","claim":"Separate ADC program","value":"GNX1021; Phase 1","as_of":"2026-10-22","source":"https://glyconex.com.tw/pipeline/","quote":"clinical-stage GNX1021"}],"undisclosed":{"text":"The checked GNX102 registry record does not disclose a restart date; GNX1021’s separate ADC progress is not evidence of a restarted GNX102 trial.","source":"https://clinicaltrials.gov/api/v2/studies/NCT04250597","as_of":"2026-10-22","quote":"GNX102","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["Registered phase and termination are confirmed; no restart or later GNX102 study was verified."]},{"id":"E14","lang":"en","question":"What biologics manufacturing services does Mycenax offer in Taiwan?","answer":[{"text":"Mycenax offers biologics CDMO services including developability assessment, cell line and process development, GMP production and regulatory documentation.","fact_ids":["f1"]},{"text":"Its ADC service page also lists antibody, linker-payload and ADC development and production, spanning candidate selection through GMP manufacturing.","fact_ids":["f2"]}],"facts":[{"id":"f1","claim":"Integrated biologics services","value":"Developability assessment, cell line development, process development, GMP production, regulatory documents","as_of":"2026-10-22","source":"https://www.mycenax.com/about.php?id=28&lang=en","quote":"cell line development"},{"id":"f2","claim":"ADC services","value":"Antibodies, linker-payloads and ADCs; candidate selection, process development and GMP manufacturing","as_of":"2026-10-22","source":"https://mycenax.com/cdmo.php?id=56","quote":"candidate ADC selection"}],"undisclosed":{"text":"The checked public service pages do not disclose project-specific prices, delivery schedules or the full list of customer programs.","source":"https://www.mycenax.com/about.php?id=28&lang=en","as_of":"2026-10-22","quote":"GMP production","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["Public service scope is verified; customer-level specifications are not public in the checked pages."]},{"id":"E17","lang":"en","question":"What are the disclosed terms of the BioNTech and DualityBio ADC licensing deal?","answer":[{"text":"For the two-asset partnership announced on April 3, 2023, DualityBio disclosed US$170 million upfront, more than US$1.5 billion in potential milestones and single-digit to double-digit tiered royalties.","fact_ids":["f1","f2","f3"]},{"text":"That agreement covered DB-1303 and DB-1311, with BioNTech holding commercial rights outside Mainland China, Hong Kong and Macau.","fact_ids":["f4"]},{"text":"BioNTech’s 2023 annual report subsequently included the August DB-1305 agreement and reported US$220 million in combined Duality upfront payments.","fact_ids":["f5"]}],"facts":[{"id":"f1","claim":"April 2023 upfront","value":"USD 170,000,000 for DB-1303 and DB-1311 together","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"$170 million"},{"id":"f2","claim":"April 2023 potential milestones","value":"Over USD 1,500,000,000","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"over $1.5 billion"},{"id":"f3","claim":"April 2023 royalty range","value":"Single-digit to double-digit tiered royalties","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"single-digit to double-digit"},{"id":"f4","claim":"Assets and territory","value":"DB-1303 and DB-1311; BioNTech rights outside Mainland China, Hong Kong and Macau","as_of":"2023-04-03","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","quote":"DB-1303 and DB-1311"},{"id":"f5","claim":"2023 combined upfront after third ADC","value":"USD 220,000,000; includes DB-1305 agreement signed in August 2023","as_of":"2023-12-31","source":"https://www.biontech.com/content/dam/corporate/pdf/BioNTech_GB23_EN_Online.pdf","quote":"$220.0 million"}],"undisclosed":{"text":"The checked public announcements and annual report do not disclose the exact royalty percentages at every tier or allocate all upfront amounts by individual asset.","source":"https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html","as_of":"2026-10-22","quote":"tiered royalties","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["April two-asset deal and later three-asset aggregate are separated; precise royalty tiers remain undisclosed."]},{"id":"E19","lang":"en","question":"What is OBI Pharma’s OBI-992 and which clinical trial is registered in the United States?","answer":[{"text":"OBI Pharma’s OBI-992 is a TROP2-targeting ADC linking an antibody to exatecan through a cleavable peptide linker.","fact_ids":["f1"]},{"text":"ClinicalTrials.gov lists NCT06480240 as a Phase 1/2 study in advanced solid tumors with U.S. sites; its status is ACTIVE_NOT_RECRUITING and its last posted update is August 8, 2025.","fact_ids":["f2","f3","f4","f5"]}],"facts":[{"id":"f1","claim":"ADC composition","value":"TROP2-targeting antibody, cleavable peptide linker and exatecan","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"Anti-TROP2 antibody drug conjugate"},{"id":"f2","claim":"Registered trial","value":"NCT06480240; Phase 1/2; advanced solid tumors","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"NCT06480240"},{"id":"f3","claim":"Registry status","value":"ACTIVE_NOT_RECRUITING","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"ACTIVE_NOT_RECRUITING"},{"id":"f4","claim":"Last posted update","value":"2025-08-08","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"2025-08-08"},{"id":"f5","claim":"US study locations","value":"United States study sites","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"United States"}],"undisclosed":{"text":"The public registry record retrieved for this card does not contain posted study results or a confirmed marketing-approval date.","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","as_of":"2026-10-22","quote":"NCT06480240","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["The registry update predates this verification; no later status is inferred."],"registry_results_posted":false},{"id":"Z02","lang":"zh","question":"藥華藥的 BESREMi 是治療什麼疾病？美國已核准哪些適應症？","answer":[{"text":"BESREMi（ropeginterferon alfa-2b-njft）在美國已核准用於成人真性紅血球增多症（PV）與成人原發性血小板增多症（ET）。","fact_ids":["f1","f2"]},{"text":"FDA 2026 年 8 月修訂仿單將其列為 interferon alfa-2b，並把 ET 列為當月新增的適應症。","fact_ids":["f3","f4"]}],"facts":[{"id":"f1","claim":"美國核准適應症：PV","value":"成人真性紅血球增多症","as_of":"2026-08","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761166s013lbl.pdf","quote":"adults with polycythemia vera","date_precision":"month"},{"id":"f2","claim":"美國核准適應症：ET","value":"成人原發性血小板增多症","as_of":"2026-08","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761166s013lbl.pdf","quote":"adults with essential thrombocythemia","date_precision":"month"},{"id":"f3","claim":"藥物類型","value":"interferon alfa-2b","as_of":"2026-08","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761166s013lbl.pdf","quote":"BESREMi is an interferon alfa-2b","date_precision":"month"},{"id":"f4","claim":"仿單適應症變更","value":"ET 適應症於 08/2026 更新","as_of":"2026-08","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761166s013lbl.pdf","quote":"Essential Thrombocythemia (1.1) 08/2026","date_precision":"month"}],"undisclosed":{"text":"本卡核對的公開仿單沒有揭露其他適應症未來取得美國核准的確定日期。","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761166s013lbl.pdf","as_of":"2026-10-22","quote":"INDICATIONS AND USAGE","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"answered"},{"id":"Z05","lang":"zh","question":"泰合的 BEQIA 美國什麼時候會有審查結果？有沒有 FDA 的確切日期？","answer":[{"text":"泰合公告的 BEQIA 美國 FDA PDUFA 審查完成目標日期是 2027 年 4 月 22 日。","fact_ids":["f1"]},{"text":"公司 2026 年 9 月 7 日發布的新聞稿稱，BEQIA（TAH3311）NDA 資料已確認完整，進入標準審查。","fact_ids":["f2"]}],"facts":[{"id":"f1","claim":"PDUFA Goal Date","value":"2027-04-22","as_of":"2026-09-07","source":"https://www.tahopharma.com/news-detail/132/","quote":"審查完成目標日期（Goal Date）為2027年4月22日"},{"id":"f2","claim":"申請階段","value":"NDA 標準審查","as_of":"2026-09-07","source":"https://www.tahopharma.com/news-detail/132/","quote":"已正式進入標準審查（Standard Review）程序"}],"undisclosed":{"text":"這份公開新聞稿沒有揭露 FDA 最終決定的實際日期與結果，也沒有附上 FDA 來函全文。","source":"https://www.tahopharma.com/news-detail/132/","as_of":"2026-10-22","quote":"獲美國食品藥物管理局（FDA）來函確認申請資料完整","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["目前只能確認公司揭露的目標日期；FDA 原始來函全文查無。"]},{"id":"Z06","lang":"zh","question":"智擎把安能得授權出去，簽約金、里程碑金和銷售權利金各是多少？","answer":[{"text":"智擎與 Merrimack 的 2011 年原始安能得（ONIVYDE）合約列出 1,000 萬美元簽約金、最高 8,000 萬美元開發及法規里程碑，以及最高 1.3 億美元銷售里程碑。","fact_ids":["f1","f2","f3"]},{"text":"Merrimack 2016 年 Form 10-K 揭露，歐洲與部分亞洲地區淨銷售額的分級權利金落在高個位數百分比至十幾個百分比的低段。","fact_ids":["f4"]}],"facts":[{"id":"f1","claim":"原始簽約金","value":"USD 10,000,000","as_of":"2011-05-05","source":"https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-10k_20161231.htm","quote":"$10.0 million upfront license fee"},{"id":"f2","claim":"原始開發與法規里程碑上限","value":"USD 80,000,000","as_of":"2011-05-05","source":"https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-10k_20161231.htm","quote":"$80.0 million"},{"id":"f3","claim":"原始銷售里程碑上限","value":"USD 130,000,000","as_of":"2011-05-05","source":"https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-10k_20161231.htm","quote":"$130.0 million"},{"id":"f4","claim":"分級銷售權利金範圍","value":"high single digits up to the low teens","as_of":"2016-12-31","source":"https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-10k_20161231.htm","quote":"high single digits up to the low teens"}],"undisclosed":{"text":"本卡核對的公開 Form 10-K 沒有揭露每一銷售級距的精確權利金百分比；上述原始里程碑上限也不是已收款金額。","source":"https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-10k_20161231.htm","as_of":"2026-10-22","quote":"tiered royalties","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["可核對原始里程碑分類與權利金區間；各級距精確百分比查無。"],"document_note":"原始合約與2016財報的後續付款揭露分開；不把2014修約後金額混成2011原始條款。"},{"id":"Z10","lang":"zh","question":"台康生技的 EG12014 是什麼藥？跟 Sandoz 有什麼授權和銷售關係？","answer":[{"text":"EG12014 是台康生技的 trastuzumab 生物相似藥，2023 年公司公告指出它已取得歐盟上市許可。","fact_ids":["f1"]},{"text":"該公告列台康負責開發與製造、Sandoz 負責授權地區商業化，並列台灣、中國、俄羅斯及部分亞洲國家為排除地區。","fact_ids":["f2","f3"]},{"text":"2019 年簽約公告揭露付款類型包括簽約金、里程碑與銷售利潤分成。","fact_ids":["f4"]}],"facts":[{"id":"f1","claim":"藥物及歐盟許可","value":"EG12014，trastuzumab biosimilar；歐盟上市許可","as_of":"2023-11-17","source":"https://www.eirgenix.com/data-112206","quote":"trastuzumab biosimilar medicine (EG12014"},{"id":"f2","claim":"角色分工","value":"台康：開發及製造；Sandoz：授權地區商業化","as_of":"2023-11-17","source":"https://www.eirgenix.com/data-112206","quote":"development and manufacturing"},{"id":"f3","claim":"2023公告排除地區","value":"台灣、中國、俄羅斯、部分亞洲國家","as_of":"2023-11-17","source":"https://www.eirgenix.com/data-112206","quote":"Taiwan, China, Russia"},{"id":"f4","claim":"付款類型","value":"upfront、milestones、profit share","as_of":"2019-04-30","source":"https://www.eirgenix.com/data-21310","quote":"profit share payments"}],"undisclosed":{"text":"本卡核對的公開公告沒有逐一列出「部分亞洲國家」，也沒有提供各項合約付款與利潤分成的精確金額或比率。","source":"https://www.eirgenix.com/data-112206","as_of":"2026-10-22","quote":"some Asian countries","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"answered","document_note":"2019簽約稿僅列China/Taiwan；本卡地區採2023較新公告，不將舊稿範圍當成當前完整條款。"},{"id":"Z13","lang":"zh","question":"逸達的 FP-001 和 CAMCEVI 是同一個產品嗎？美國由誰銷售？","answer":[{"text":"FP-001 是逸達 CAMCEVI 的開發代號；2022 年美國上市公告將 CAMCEVI 42 毫克六個月針劑對應為 FP-001 50 毫克。","fact_ids":["f1"]},{"text":"公告指出它用於晚期前列腺癌，美國市場銷售由 Intas 的美國子公司 Accord BioPharma 負責。","fact_ids":["f2","f3"]}],"facts":[{"id":"f1","claim":"代號與商品對應","value":"CAMCEVI 42 mg 六個月針劑＝FP-001 50 mg","as_of":"2022-04-04","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","quote":"即FP-001 50毫克"},{"id":"f2","claim":"用途","value":"晚期前列腺癌","as_of":"2022-04-04","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","quote":"治療晚期前列腺癌"},{"id":"f3","claim":"美國銷售公司","value":"Accord BioPharma（Intas 美國子公司）","as_of":"2022-04-04","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","quote":"由Accord BioPharma 負責CAMCEVI於美國之市場銷售"}],"undisclosed":{"text":"本卡核對的公開上市公告沒有揭露美國授權的精確銷售權利金比率。","source":"https://www.foreseepharma.com/tw/news/category/%E6%96%B0%E8%81%9E%E7%99%BC%E4%BD%88/accord_biopharma__in_partnership_with_foresee_pharmaceuticals__launches_camcevi___leuprolide__injection_emulsion_in_the_u_s__for_the_treatment_of_advanced_prostate_cancer_in_adults","as_of":"2026-10-22","quote":"2021年3月與Intas Pharmaceuticals簽訂美國市場授權合作","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"answered"},{"id":"Z14","lang":"zh","question":"永昕生醫在做什麼？它的生物藥 CDMO 和台康生技差在哪？","answer":[{"text":"永昕官網將公司定位為生物藥 CDMO，服務包括可開發性評估、細胞株與製程開發、GMP 生產及法規文件。","fact_ids":["f1"]},{"text":"永昕也列出抗體、linker-payload 與 ADC 的委託開發製造；台康的公司介紹則明列 CDMO 與產品開發並行的雙軌模式。","fact_ids":["f2","f3"]}],"facts":[{"id":"f1","claim":"永昕服務","value":"評估、細胞株、製程、GMP生產、法規文件","as_of":"2026-10-22","source":"https://www.mycenax.com/about.php?id=28&lang=en","quote":"regulatory documents"},{"id":"f2","claim":"永昕ADC服務","value":"抗體、linker-payload與ADC開發製造","as_of":"2026-10-22","source":"https://mycenax.com/cdmo.php?id=56","quote":"antibodies, linkers-payloads, and ADCs"},{"id":"f3","claim":"台康營運模式","value":"CDMO與產品開發並行","as_of":"2026-08-28","source":"https://www.formosapharma.com/formosa-pharmaceuticals-files-clinical-trial-application-for-tsy-110-an-antibody-drug-conjugate-biosimilar-targeting-her2-positive-breast-cancers/","quote":"combining CDMO with Product Development"}],"undisclosed":{"text":"本卡核對的兩家公司公開介紹沒有提供可直接同口徑比較的報價、交期或各客戶專案臨床階段。","source":"https://www.mycenax.com/about.php?id=28&lang=en","as_of":"2026-10-22","quote":"biopharmaceutical services and solutions","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["可比的是公開服務與營運模式；價格、交期與同口徑產能比較查無。"]},{"id":"Z17","lang":"zh","question":"AstraZeneca 跟 insitro 的合作，公開的簽約金和最高里程碑金是多少？","answer":[{"text":"insitro 於 2026 年 10 月 15 日公告與 AstraZeneca 合作，公開的簽約金承諾為 4,000 萬美元，潛在里程碑最高約 14.6 億美元。","fact_ids":["f1","f2"]},{"text":"公告另列未來全球商業銷售的個位數百分比權利金。","fact_ids":["f3"]}],"facts":[{"id":"f1","claim":"Upfront commitment","value":"USD 40,000,000","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"$40 million upfront"},{"id":"f2","claim":"Potential milestone ceiling","value":"Approximately USD 1,460,000,000","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"$1.46 billion"},{"id":"f3","claim":"Royalties","value":"Single-digit royalties on potential global commercial sales","as_of":"2026-10-15","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","quote":"single-digit royalties"}],"undisclosed":{"text":"這份公開新聞稿沒有揭露簽約金是否已實際入帳，也沒有公布各里程碑門檻與精確權利金比率。","source":"https://www.insitro.com/news/insitro-announces-a-strategic-collaboration-with-astrazeneca-for-ai-enabled-discovery-of-novel-therapeutics-for-mash-and-cardiomyopathies/","as_of":"2026-10-22","quote":"will receive","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["公告是付款承諾；實際收款與里程碑細項查無。"]},{"id":"Z19","lang":"zh","question":"台灣浩鼎的 OBI-992 是什麼 ADC？美國臨床試驗登錄進度到哪？","answer":[{"text":"OBI-992 是以 TROP2 為標靶、透過可切割胜肽連接子連接 exatecan 的 ADC。","fact_ids":["f1"]},{"text":"ClinicalTrials.gov 登錄 NCT06480240 為晚期實體腫瘤的第 1/2 期試驗，含美國試驗中心，狀態為進行中但不再收案；本次讀取的最後公開更新日期是 2025 年 8 月 8 日。","fact_ids":["f2","f3","f4","f5"]}],"facts":[{"id":"f1","claim":"ADC composition","value":"TROP2-targeting antibody, cleavable peptide linker and exatecan","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"Anti-TROP2 antibody drug conjugate"},{"id":"f2","claim":"Registered trial","value":"NCT06480240; Phase 1/2; advanced solid tumors","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"NCT06480240"},{"id":"f3","claim":"Registry status","value":"ACTIVE_NOT_RECRUITING","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"ACTIVE_NOT_RECRUITING"},{"id":"f4","claim":"Last posted update","value":"2025-08-08","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"2025-08-08"},{"id":"f5","claim":"US study locations","value":"美國試驗中心／United States study sites","as_of":"2025-08-08","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","quote":"United States"}],"undisclosed":{"text":"本卡讀取的公開登錄未刊出試驗結果，也沒有揭露 OBI-992 的確定上市核准日期。","source":"https://clinicaltrials.gov/api/v2/studies/NCT06480240","as_of":"2026-10-22","quote":"NCT06480240","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","limitations":["登錄最後更新早於本次查核；不能以查核日當成試驗狀態更新日。"],"registry_results_posted":false}]